Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Maintenance therapy with the oral PI ixazomib significantly prolongs PFS following ASCT in multiple myeloma

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 13.12.18
Views: 402
Rating:

Dr Francesca Gay - University of Torino, Torino, Italy

Dr Fransesca Gay speaks to ecancer at ASH 2018 about the study looking at maintenance therapy with the oral proteasome inhibitor ixazomib in patients with newly diagnosed multiple myeloma.

She explains that it was found that this maintenance with ixazomib significantly improved progression-free survival with results of 26.5 months compared to the placebo of 21 months.

Dr Gay also reports that an advantage was seen for patients with MRD negativity at the beginning of the study with these patients achieving a median progression-free survival of 38 months.

Related videos

follow us

Donate to ecancer


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation